Neurofibromatosis type 1: diagnosis and recent advances
- 10 June 2010
- journal article
- Published by Taylor & Francis Ltd in Expert Opinion on Medical Diagnostics
- Vol. 4 (4), 307-322
- https://doi.org/10.1517/17530059.2010.494660
Abstract
Importance of the field: Neurofibromatosis type 1 (NF1) is a familial tumour predisposition syndrome with no current treatment regime. Neurofibromin, the NF1 gene product, is a Ras-GAP protein that downregulates Ras and when inactivated leads to increased cell growth, proliferation and eventually tumorigenesis. The Ras family proteins have a central role in cell biology and are of prime importance in cancer development. Areas covered in this review: This article reviews recent advances from the past 5 years, covering aspects of molecular and clinical diagnosis of NF1, genotype/phenotype studies, the RASopathies, NF1 tumorigenesis, mouse NF1 models and potential therapies. What reader will gain: The reader is introduced to recent advances in NF1 that focus on clinical and molecular diagnosis. The reader should gain a better understanding of the molecular basis of NF1 and of other NF1-like syndromes, and the challenges presented for clinical management. Take home message: A molecular diagnosis can usually be made in most NF1 patients using a battery of gene screening techniques. The sensitivity and specificity of mutation detection will increase with the introduction of new technologies and new bioinformatic tools. Pathogenic somatic mutations of the NF1 gene are increasingly being identified in tumours not usually associated with NF1, a clear indication that neurofibromin has a much wider biological role and has an importance far beyond NF1.Keywords
This publication has 90 references indexed in Scilit:
- What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: New FrontiersAmerican Journal of Medical Genetics Part A, 2010
- PTEN dosage is essential for neurofibroma development and malignant transformationProceedings of the National Academy of Sciences of the United States of America, 2009
- Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival geneEMBO Molecular Medicine, 2009
- Cell of Origin and Microenvironment Contribution for NF1-Associated Dermal NeurofibromasCell Stem Cell, 2009
- Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse ModelCancer Cell, 2009
- Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone MarrowCell, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1JAMA, 2008
- The Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem CellsCancer Cell, 2008
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences of the United States of America, 1971